期刊文献+

调强放疗联合培美曲塞和顺铂同期化疗局部晚期非小细胞肺癌的临床研究 被引量:16

Clinical study of treatment of locally advanced non-small cell lung cancer by intensity modulated irradiation combined with Pemetrexed and Cisplatin
原文传递
导出
摘要 目的 探讨调强放疗结合培美曲赛和顺铂同期化疗局部晚期非小细胞肺癌的疗效及副反应.方法 42例Ⅲ期非小细胞肺癌患者(ⅢA期25例,ⅢB期17例)接受DT66 Cy调强放疗,疗中给予培美曲塞500 mg/m2静脉滴注第1天,顺铂75 mg/m2静脉滴注第1天,21 d为1个周期,共4个周期.放化疗在同大开始进行,先化疗后放疗.2例放疗总量54 Gy,2例56 Gy;3例完成了2周化疗,1例完成了 3周化疗.结果 34例患者完成了治疗计划.全组总有效率为79%,1年总生存率为65%.≥3级骨髓抑制2例,3级放射性食管炎3例,≥2级放射性肺炎4例,3级黏膜炎1例.结论 培美曲赛和顺铂同期放化疗局部晚期非小细胞肺癌患者具有较好的近期疗效,副反应可耐受. Objective To observe the therapeutic effect and toxicity of chemoradiation of locally advanced non-small cell lung cancer by intensity modulated irradiation combined with pemetrexed and cisplatin. Methods Fourty-two patients presented with Ⅲ - stage non-small cell lung cancer(Ⅲ、 25 patients, ⅢB 17 patients)received concurrent chemoradiotherapy. Intensity modulated irradiation technique was used to the total dose of 66 Gy and concurrent chemotherapy consisted of pemetrexed 500 mg/m2 on Day 1 and cisplatin 75 mg/m2 on Day 1 by intravenous infusion once every 3 weeks at the initiation of radiation.Patients received 4 cycles of chemotherapy. Results Thirty-four patients finished the whole of therapeutic schedule. And 2 patients received radiation with total dose of 54 Gy, 2 patients 56 Gy;3 patients received 2 cycles of chemotherapy, 1 patients 3 cycles of chemotherapy. Total effective rate was 79%. There were 2 patients with ≥3 grade marrow depression, 3 patients with 3 grade radiation esophagitis, 4 patients with ≥2 radiation pneumonitis, and 1 patient with 3 grade mucositis. The 1-year survival rate was 65%.Conclusion Recent effect was favourable and toxicity was tolerable for chemoradiation of locally advanced non-small cell lung cancer by intensity modulated irradiation combined with pemetrexed and cisplatin.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2011年第1期14-17,共4页 Chinese Journal of Radiation Oncology
关键词 非小细胞肺/同期化放疗法 放射疗法 调强 化学疗法 培美曲塞和顺铂 近期效果 Carcinoma, non-small cell lung/concurrent chemoradiotherapy Radiotherapy,intensity modulated Chemotherapy, pemetrexed and cisplatin Recent effect
  • 相关文献

参考文献13

  • 1张志庸,郭峰,崔玉尚,李单青,李力,徐晓辉,戈烽,郭惠琴,李泽坚.北京协和医院外科治疗肺癌生存率变化分析[J].中国肺癌杂志,2005,8(2):124-128. 被引量:16
  • 2Chen M,Jiang G,Fu X.Prognostic factors for local control in non-small-cell lung cancer treated with definitive radiation therapy.Am J Clin Oncol,2002,25:76-80.
  • 3Lau D,Leigh B,Gandara D,et al.Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage Ⅲ non-small-cell lung cancer:a california cancer consortium phase Ⅱ trial.J Clin Oncol,2001,19:442-447.
  • 4Yokes EE,Herndon JE,Kelley MJ,et al.Induction chemotherapy followed by concomitant chemoradiotherapy(CT/XRT)versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer(NSCLC):initial analysis of a randomized phase Ⅲ trial.J Clin Oncol,2004,22:7005.
  • 5Movsas B,Scott C,Langer C,et al.Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation:radiation therapy oncology group trial 98-01.J Clin Oncol,2005,22:2145-2154.
  • 6李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 7Scagliotti GV,Kortsik C,Dark GG,et al.Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer:a multicenter,randomized,phase Ⅱ trial.Clin Cancer Res,2005,11(2 Pt 1):690-696.
  • 8Zinnex RG,Fossella FV,Gladish GW,et al.Phase Ⅱ study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.Cancer,2005,104:2449-2456.
  • 9Seiwert TY,Connell PP,Mauer AM,et al.A phase Ⅰ study of pemetrexed,carboplatin,and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.Clin Cancer Res,2007,13(2 Pt 1):515-522.
  • 10Fournel P,Robinet G,Thomas P,et al.Randomized phase Ⅲ trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer:groupe lyon-saint-etienne d'oncologie thoracique-groupe fraénais de pneumo-cancérologie NPC 95-01 Study.J Clin Oncol,2005,23:5910-5917.

二级参考文献32

  • 1廖美琳 徐昌文 等.2636例原发支气管肺癌手术后生存率的分析[J].中华肿瘤杂志,1988,8(1):34-36.
  • 2丁嘉安 周晓明 等.2048例原发性支气管肺癌的外科疗效分析[J].中华医学杂志,1988,68(1):23-26.
  • 3张大为,张汝刚,程贵余,孙克林,方德康,刘向阳,毛友生,汪良俊,张德超,杨林.肺癌外科治疗[J].心肺血管病杂志,1997,16(1):3-10. 被引量:28
  • 4[1]Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol, 1999, 26 (2 Suppl 6) :3
  • 5[2]Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.Semin Oncol. 1999, 26 (2 Suppl 6): 11
  • 6[3]Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition,polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 1999, 26 (2 Suppl 6):42
  • 7[4]Calvert H. MTA, a novel multitargeted antifolate, from preclinical to phase Ⅰ and beyond: Summary and conclusions. Semin Oncol, 1999, 26 (2 Suppl 6): 105
  • 8[5]Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol, 1999, 26 (2 Suppl 6) :68
  • 9[6]Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer, 1998, 78 (Suppl 3) :35
  • 10[7]Newell DR. Clinical pharmacokinetics of antitumor antifolates.Semin Oncol, 1999, 26 (2 Suppl 6):74

共引文献86

同被引文献119

引证文献16

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部